Document:

Exhibit
10.41

Quotation

Development
of a Heparin/Lidocain

Sterile Injectable

QTE-USJ-0002.01

July 22, 2005

Confidential for Urigen,
Inc.

Client Contact: Mike
Flashner, Ph.D.

1701 Jackson Street, Suite 102

San Francisco, CA 94109

Phone: (650) 627-8140

 

	
  Account Manager: Suzanne Dorsey

  	
   

  	
  Technical Contact:
  Sharon Wu, Ph.D.

  
	
  Phone: 209-834-0270

  	
   

  	
  Phone:  858-547-7842

  

 

	
  

  	
   

  	
  BioPharmaceuticat
  Product Development

  
	
  

  	
   

  	
  Pharmaceutical
  Product Development

  
	
   

  	
  Clinical
  Packaging Services

  
	
   

  	
  Analytical
  Chemistry Services

  
	
   

  	
  Scientific
  and Regulatory Consulting

  
	
   

  	
  Pulmonary
  and Nasal Product Development

  
	
   

  	
   

  	
  Clinical
  and Small Scale Commercial Manufacturing

  

 

Executive Summary

Cardinal Health PTS, LLC (“Cardinal Health”), by and through its
Biotechnology and Sterile Life Sciences group, will perform formulation
development for Urigen, Inc. (“Urigen”). The total cost for this project is
currently estimated to be $74,400 over a period of approximately two to three
months for development activities and six months for stability testing.

Section 1.     Version History

Table
1:   Revisions

	
  Version

  	
   

  	
  Date Issued

  	
   

  	
  Reason(s)

  	
   

  
	
  00

  	
   

  	
  07/14/05

  	
   

  	
  New Issue

  	
   

  
	
  01

  	
   

  	
  07/22/05

  	
   

  	
  Reduced the number of investigational hours to be performed with
  client approval in Section 6.3.

  	
   

  

 

Section 2.     Scope of Work

A solution of lidocain and heparin that has been alkalinized with bicarbonate,
injected  into the bladder, has
been shown to immediately reduce symptoms of urgency and pain in patients
suffering from interstitial cystitis. Significant symptom relief was achieved
using both 1% and 2% lidocain
solutions.

Cardinal Health will acquire analytical methods necessary for product
analysis. Short-term stability will be evaluated on two dosage forms that will
contain 8 mL of lidocain (2%), 4 mL of heparin (10,000 USP units per mL),
with and without 3  mL of 8.4%
sodium bicarbonate, at a pH of 8.0. The product will preferably consist of a 15
mL solution that is ready for injection. A  laboratory-scale
filtration process for manufacturing sterile drug product will also be
developed by Cardinal Health.

2.1.     Safety

2.1.1.    Cardinal Health’s
Responsibilities

Cardinal Health will assess all vendor and Urigen MSDSs and all
handling data for the samples/materials associated with this project. When
samples/materials are categorized as a Controlled Drug Substance (CDS) and/or
Class 4 or above, the samples/materials will require special handling precautions
and are subject to a Safety Handling Surcharge for all handling and analyses
directly associated with the samples/materials.

2.1.2. Urigen’s Responsibilities

Urigen will provide an MSDS and all sample/material handling data for
the samples/materials associated with this project. If samples/materials have
any special handling considerations, Urigen will notify Cardinal Health prior
to the initiation of the project.

	
  9240 Trade Place, Suite
  100  •  San Diego, CA 92126

  
	
  Direct: (858)
  547-7800  •  Facsimile: (858)
  693-5989  •  www.cardinal.com/pts

  
	
  CONFIDENTIAL

  

 

 2
 

2.2.     Methods/Documentation

2.2.1.    Cardinal Health’s
Responsibilities

Cardinal Health will review all project-related documentation and
methods received from Urigen associated with this project.

2.2.2. Urigen’s Responsibilities

Urigen will provide all available project-related documentation and
methods to be used for this project.

2.3.     Sample/Materials

2.3.1.    Cardinal Health’s
Responsibilities

Cardinal Health will, as necessary, log in all samples/materials
according to current Standard Operating Procedures. Upon issuance of the final
report or Certificate of Analysis, samples/materials will be stored in
quarantine at Cardinal Health for a period of 30 days. After the 30-day
quarantine, samples/materials will be disposed of at Cardinal Health unless
notified otherwise by Urigen.

2.3.2.    Urigen’s Responsibilities

If available, Urigen will provide all samples/materials necessary to
perform this project. The samples/materials should arrive at Cardinal Health
with all proper documentation. If samples/materials are not available, Urigen
will request Cardinal Health to purchase all necessary samples/materials needed
to perform this project. If return shipment is requested, Urigen will notify
Cardinal Health prior to the disposition of samples/materials.

Section 3.     Project Activities

3.1.     Cardinal Health’s Responsibilities

A.                      Acquire
methods for the analysis of lidocain hydrochloride injection, USP, heparin
sodium injection, USP, and sodium bicarbonate injection, USP.

B.                      Evaluate
short-term stability of two dosages forms stored at 5°C, 30°C and 40°C for 14
days. Time points will include time zero, 12hr, 24hr, 3 days, 7 days and 14
days. Testing at each time point will include pH, appearance and assay.

C.                      Develop
a process for sterile filtration.

D.                      Manufacture
non-GMP batch of probe formulation.

E.                        Conduct
stability program on the non-GMP batch (6-month stability study with samples
stored at refrigerated condition, room temperature and an accelerated
condition).

3.2.     Urigen’s Responsibilities

Urigen will sign the Protocol and provide a technical contact that will
be available for technical discussions and to make decisions that are needed in
reference to this project. Urigen will not

	
  9240 Trade Place, Suite
  100  •  San Diego, CA 92126

  
	
  Direct: (858)
  547-7800  •  Facsimile: (858)
  693-5989  •  www.cardinal.com/pts

  
	
  CONFIDENTIAL

  

 

 3
 

use any samples/materials shipped from Cardinal Health
for this project in a manner that is inconsistent with the scope of this
project.

Section 4.     Specifications

4.1.               Cardinal Health’s
Responsibilities

Cardinal Health will document the specifications in the Protocol.

4.2.     Urigen’s
Responsibilities

Urigen will provide all specifications necessary to perform this
project.

Section 5.     Scheduling/Deliverables

5.1.               Scheduling

Cardinal Health must receive a signed Quotation,
containing Standard Terms and Conditions, a Purchase Order number, a signed
Protocol, and all samples/materials in order for this project to be scheduled.
Once scheduled, Urigen will be notified by Cardinal Health of the anticipated
start and completion date of the project activities.

Rush services are available at Urigen’s request, if
rush services are requested, additional costs will be incurred, ranging from 10
to 100% of the project cost and depending upon on the lead-time provided and
Urigen-requested turnaround time.

5.2.     Communication

In order to establish a collaborative relationship
between Urigen and Cardinal Health, Cardinal Health will appoint a Project
Coordinator to serve as a point of contact for Urigen and to oversee progress
on this project. Upon initiation of the project, Cardinal Health and Urigen
will establish a communication plan, if requested, that may include conference
calls and visits.

5.3.     Deliverables

A report or Certificate of Analysis will be issued
upon completion of the project activities or at the end of each project phase.

	
  9240 Trade Place, Suite 100  •  San
  Diego, CA 92126

  
	
  Direct: (858) 547-7800  •  Facsimile:
  (858) 693-5989  •  www.cardinal.com/pts

  
	
  CONFIDENTIAL

  

 

 4

Section 6.     Cost Proposal

6.1.     Project Cost

Table 2:   Total Estimated Project Costs

	
  Cardinal Health Activity

  	
   

  	
  Estimated

  Cost

  	
   

  
	
  Project Initiation Fee

  	
   

  	
  Waived

  	
   

  
	
  Acquisition of
  Analytical Methods (for the analysis of lidocain hydrochloride injection USP,
  heparin sodium injection USP, and sodium bicarbonate injection USP)

  	
   

  	
  $

  	
  15,000

  	
   

  
	
  Short-term Stability
  Study

  	
   

  	
  $

  	
  20,000

  	
   

  
	
  Development of Sterile
  Filtration Process

  	
   

  	
  $

  	
  10,000

  	
   

  
	
  Manufacture of Small
  Scale non-GMP Batch

  	
   

  	
  $

  	
  5,000

  	
   

  
	
  Stability Testing of
  non-GMP batch (details are provided in Table 3)

  	
   

  	
  $

  	
  24,400

  	
   

  
	
  Total
  Estimated Protect Cost =

  	
   

  	
  $

  	
  74,400

  	
   

  

 

Table 3:   Stability Cost Table

	
  

  	
   

  	
  Test Interval (months)

  	
   

  
	
  Condition

  	
   

  	
  T0

  	
   

  	
  0.5

  	
   

  	
  1

  	
   

  	
  3

  	
   

  	
  6

  	
   

  
	
  Drug Product Storage at 5°C

  	
   

  	
   

  	
   

  	
  $

  	
  3,200

  	
   

  	
  $

  	
  3,200

  	
   

  	
  $

  	
  3,200

  	
   

  	
  $

  	
  3,200

  	
   

  
	
  Drug Product Storage at 25°C

  	
   

  	
  $

  	
  3,200

  	
   

  	
  $

  	
  1,200

  	
   

  	
  $

  	
  1,200

  	
   

  	
  $

  	
  1,200

  	
   

  	
  $

  	
  1,200

  	
   

  
	
  Drug Product Storage at 40°C

  	
   

  	
   

  	
   

  	
  $

  	
  1,200

  	
   

  	
  $

  	
  1,200

  	
   

  	
  $

  	
  1,200

  	
   

  	
  N/A

  	
   

  
	
  Total
  Cost per Timepoint =

  	
   

  	
  $

  	
  3,200

  	
   

  	
  $

  	
  5,600

  	
   

  	
  $

  	
  5,600

  	
   

  	
  $

  	
  5,600

  	
   

  	
  $

  	
  4,400

  	
   

  
	
  Stability Testing Subtotal =

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  $

  	
  24,400

  	
   

  

 

NOTE: The pricing
for the accelerated conditions ($1,200 per time point) in the cost table above
is provided under the assumption that analysis will be performed concurrently
with samples from the 5°C condition.

6.2.     Additional Fees

If copies of raw data are requested in the course of
an active project, Urigen will be invoiced at $150/hour for time required to
generate and compile the data.

All requested samples/materials purchased by Cardinal
Health for this project will be invoiced to Urigen, at cost. Non-standard or
special instrumentation or equipment required solely for Urigen’s project will
be invoiced to Urigen following Urigen approval.

6.3.     Revisions to Pricing

Cardinal Health reserves the right to revise quoted
costs for any project as a result of initial scope change, revisions in
Protocols, modifications of test methods, final review of test

	
  9240 Trade Place, Suite 100  •  San
  Diego, CA 92126

  
	
  Direct: (858) 547-7800  •  Facsimile:
  (858) 693-5989  •  www.cardinal.com/pts

  
	
  CONFIDENTIAL

  

 

 5
 

methods, undocumented requirements, retesting or
resynthesis, or any unforeseen difficulty in executing the project. The
additional work will be performed based on written agreement from Urigen and
will be documented on a Cardinal Health Quotation Amendment Request (QAR).

All required investigational work (such as OOS
investigations, troubleshooting chromatographic methods, etc.) may be conducted
without prior approval from Urigen, for up to 4 scientist hours per occurrence.
If the additional work requires going beyond 4 hours, Urigen will be contacted
prior to continuation. All investigational retesting performed that is not
directly due to a Cardinal Health error will be invoiced to Urigen.

Section 7.     Invoicing and Payment Terms

7.1.               Invoicing

Cardinal Health will issue monthly invoices for work in process.

7.2.               Payment Terms

Payments toward all invoices are due within 30 days of
receipt of invoice and are non-refundable. Any applicable wire transfer fee
must be included in the payment issued to Cardinal Health. Remit all payments
to:

Cardinal Health PTS, LLC 

4673 Collections Center Drive 

Chicago, IL 60693 

Phone: 919-481-4855

Section 8.     Additional Project Terms

8.1.     Termination
/ Cancellation

Either party may terminate the Project or any portion
thereof at any time by providing forty-five (45) days written notice. In the
event of a termination by Urigen, Cardinal Health will promptly scale down the
affected portion of the Project to avoid (or minimize, where non-cancelable)
any further related expenses. On the effective date of termination, Urigen will
make payment to Cardinal Health in an amount equal to the costs incurred by
Cardinal Health for all work performed prior to the effective date, any costs
necessary to scale-down the Project, any non-cancelable commitments made by
Cardinal Health prior to notice of termination, and any cancellation fees
pursuant to the details below. Additionally, Cardinal Health will invoice
Urigen the cost of any sample/materials, reference materials, equipment, and
supplies purchased by Cardinal Health specifically for this project.

If this Project is cancelled by Urigen for purposes
within their control, Cardinal Health reserves the right to invoice Project
Cancellation fees according to the following schedule: acceptance of quotation
but no approved protocol, $500; acceptance of protocol but no laboratory work,
$1,500; and after laboratory work has begun, time plus 10%.

	
  9240 Trade Place, Suite 100  •  San
  Diego, CA 92126

  
	
  Direct: (858) 547-7800  •  Facsimile:
  (858) 693-5989  •  www.cardinal.com/pts

  
	
  CONFIDENTIAL

  

 

 6

8.2. Standard Terms and
Conditions

All work performed under this quotation is subject to the Standard
Terms and Conditions between Cardinal Health and Urigen as defined as follows:

A.       [Illegible] By Cardinal
Health.

B.                        Audits.
Client may conduct one quality assurance facility audit per year at no cost.
Additional audits will be invoiced separately at the current rate for such
services.

C.                        Regulatory
Inspections. Cardinal Health will promptly notify Client of any regulatory
inspections directly relating to the Project. Client accepts reasonable and
documented costs charged by a regulatory authority for inspections directly
related to the Project.

D.                       Price
Changes. Cardinal Health may revise the prices provided in this Quotation
if (i) Client’s requirements or any Client-provided Information is inaccurate
or incomplete, (ii) Client revises Cardinal Health’s responsibilities, the
Specifications, the Project instructions, procedures, assumptions, processes,
test protocols, test methods or analytical requirements, to the extent
applicable to the Project, or (iii) for such other reasons set forth in the
Quotation.

E.                         Payments.
Cardinal Health will invoice Client as set forth in the Quotation. Cardinal
Health charges a late payment fee of 1 1⁄2%  per
month for payments not received by the date specified in the Quotation. Failure
to bill for interest due shall not be a waiver of Cardinal Health’s right to
charge interest.

F.                         Taxes.
Client will pay any sales, use, gross receipts, compensating or other taxes,
licenses, or fees (excluding Cardinal Health’s net income and franchise taxes)
to be paid by Cardinal Health to any tax jurisdiction arising from the Project.

G.                        Hazardous
Materials. Client warrants to Cardinal Health that no specific safe
handling instructions are applicable to any substance or material provided by
Client to Cardinal Health, except as disclosed to Cardinal Health in writing by
the Client in sufficient time for review and training by Cardinal Health prior
to delivery. Where appropriate or required by law, Client will provide a
Material Safety Data Sheet for all Client-provided materials, finished Product,
and reference standards.

H.                       Shipment.
Unless otherwise specified in the Quotation, all product, raw materials and
components shipped by Cardinal Health are delivered F.O.B. Cardinal Health’s
facilities.

I.                            Limitations
of Liability. NOTWITHSTANDING ANY OTHER PROVISION IN THIS QUOTATION,
CARDINAL HEALTH’S LIABILITY UNDER THIS QUOTATION SHALL NOT EXCEED THE
TOTAL AMOUNT PAID BY CLIENT TO CARDINAL HEALTH HEREUNDER (BUT EXCLUDING FEES
FOR PROCURING COMPARATOR DRUG). NOTWITHSTANDING THE FOREGOING, CARDINAL HEALTH’S
LIABILITY FOR LOSSES TO API, BULK DRUG PRODUCT OR OTHER MATERIALS PROVIDED BY
CLIENT, WHETHER OR NOT INCORPORATED INTO FINISHED PRODUCT, SHALL NOT EXCEED
$5,000. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY
SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES, WHETHER OR NOT
FORESEEABLE, ARISING FROM THE PROJECT OR THIS QUOTATION.

J.                           Confidentiality.
All information disclosed by a party in connection with this Quotation shall be
confidential information, unless such information is (1) already known to the
receiving party, as evidenced by written records; (2) independently developed
or discovered by the receiving party without the use of the disclosing party’s
confidential information, as evidenced by written records; (3) in the public
domain other than through the fault of the receiving party; (4) disclosed to
the receiving party by a third party not in breach of a duty of confidentiality
owed to the disclosing party; or (5) required to be disclosed by law, or court
or administrative order; provided, that the receiving party first gives
prompt notice thereof to the disclosing party. Neither party shall, without the
other party’s prior written consent, use the confidential information of the
other party or disclose such information to anyone other than employees of the
receiving party or its affiliated entities who require such information to
perform such party’s obligations under this Quotation. This undertaking shall
survive for 7 years following termination of this Quotation.

K.                       Intellectual
Property. All Cardinal Health Materials, including without limitation, all
improvements, developments, derivatives or modifications to the Cardinal Health
Materials, shall be owned exclusively by Cardinal Health. All Client Materials,
including, without limitation, all improvements, developments, derivatives or
modifications to the Client Materials shall be owned exclusively by Client. All
improvements, developments, derivatives or modifications to a Generic Drug, if
any, shall be owned jointly by Cardinal Health and Client For purposes hereof, “Cardinal
Health Materials” means all Cardinal Health proprietary information,
intellectual property, and developments, including without limitation, all
patents, patent applications, know-how, inventions, designs, concepts,
improvements, technical information, manuals, instructions or specifications,
which are owned, licensed or used by Cardinal Health in developing,
formulating, manufacturing, filling, processing (sterile or non-sterile),
packaging, analysis or testing pharmaceutical products and the packaging
equipment, processes or methods of

	
  9240 Trade Place, Suite
  100  •  San Diego, CA 92126

  
	
  Direct: (858)
  547-7800  •  Facsimile: (858)
  693-5989  •  www.cardinal.com/pts

  
	
  CONFIDENTIAL

  

packaging, or any improvements to any of the foregoing. For purposes
hereof, “Client Materials” means all proprietary information, intellectual property,
and developments, including without limitation, all patents, patent
applications, know-how, inventions, designs, concepts, improvements, technical
information, manuals, instructions or specifications, which are owned, licensed
or used by Client relating to Client’s patented API (specifically excluding any
API that does not have any unexpired patents owned or licensed by Client; each
such API, a “Generic Drug”) or the formulation thereof.

L.                         Warranties.
Cardinal Health will perform the Project in accordance with the Specifications,
Project Instructions and United States current Good Manufacturing Practices or
current Good Laboratory Practices, as applicable. THE WARRANTIES SET FORTH IN
THE QUOTATION AND THESE STANDARD TERMS AND CONDITIONS ARE THE SOLE AND
EXCLUSIVE WARRANTIES MADE BY CARDINAL HEALTH TO CLIENT AND THERE ARE NO OTHER
WARRANTIES, REPRESENTATIONS OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER
EXPRESS OR IMPLIED, REGARDING THE PRODUCTS OR PROJECT, INCLUDING WITHOUT
LIMITATION ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY,
NONINFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.

M.                    Client
Obligations. Unless otherwise agreed to by the parties in writing, Client
is solely responsible to (i) provide complete and accurate scientific data regarding
the Project, (ii) if applicable, review and approve all in-process and finished
product test results to ensure conformity of such results with the product
Specifications, regardless of which party is responsible for finished product
release, (iii) prepare all submissions to regulatory authorities, and (iv)
perform such other obligations of Client set forth in the Quotation.

N.                       Indemnification.
Client will indemnify and hold harmless Cardinal Health, its affiliates and
their officers, directors, agents and employees against any third party claim
arising directly or indirectly from (a) the manufacture, promotion, marketing,
distribution or sale of the Product, (b) use or exposure to the Product, (c)
exposure to materials provided by Client, (d) negligence or willful misconduct
of Client, (e) breach of this Quotation by Client, or (f) use of any
intellectual property provided by Client to Cardinal Health. Cardinal Health
will indemnify Client for any third party claim arising from (i) any negligence
or willful misconduct by Cardinal Health, or (ii) Cardinal Health’s breach of
this Quotation.

O.                       Set-Off.
Without limiting Cardinal Health’s rights under law or in equity, Cardinal
Health and its affiliates, parent or related entities, collectively or
individually, may exercise a right of set-off against all amounts due to
Cardinal Health from Client. For purposes of this Section, Cardinal Health, its
affiliates, parent or related entitles shall be deemed to be a single creditor.

P.                         Force
Majeure. Neither party will be liable for any failure to perform or for
delay in performance resulting from any cause beyond its reasonable control,
including without limitation, acts of God, fires, floods, or weather; strikes
or lockouts, factory shutdowns, embargoes, wars, hostilities or riots,
shortages in transportation; provided, however, that if Cardinal Health cannot
complete an order within ninety (90) days due to any such cause, Client may
terminate this Quotation without liability to Cardinal Health.

Q.                       Use
and Disposal. Client represents and warrants to Cardinal Health that Client
will hold, use and/or dispose of Product and materials provided by Cardinal
Health in accordance with all applicable laws, rules and regulations.

R.                        Record
Retention. Unless the parties otherwise agree in writing, Cardinal Health
will retain batch, laboratory and other technical records for the minimum
period required by applicable law.

S.                         Independent
Contractor. It is expressly agreed that Cardinal Health and Client shall be
independent contractors and that the relationship between the two parties shall
not constitute a partnership, joint venture or agency.

T.                        Publicity.
Neither party will make any press release or public disclosure regarding this
Quotation or the transactions contemplated hereby without the other party’s
express prior written consent, except as required by applicable law or by any
governmental agency, in which case the party required to make the press release
or public disclosure shall use commercially reasonable efforts to obtain the
approval of the other party as to the form, nature and extent of the press
release or public disclosure prior to making the public disclosure.

U.                       Authority.
Client grants Cardinal Health full authority to use any Client supplied
materials or substances. Client and Cardinal Health each represent and warrant
that it has taken all necessary action on its part to authorize the execution
and delivery of this Quotation and this Quotation has been duly executed and
delivered on behalf of such party, and constitutes a legal, valid, binding
obligation, enforceable against such party in accordance with its terms.

V.                        Amendment
& Precedence. This Quotation constitutes the entire agreement of the
parties related to the Project and may not be modified without the other party’s
prior written consent. These Standard Terms and Conditions supercede any
conflicting terms and conditions set forth in the Quotation. Any previous
written acknowledgement, statement or prior understanding between the parties
related to the Project is superceded by this Quotation.

W.                   Dispute
Resolution. If a dispute arises between the parties in connection with this
Quotation, the respective presidents or Senior Executives of Cardinal Health
and Client shall first, attempt to resolve the dispute. If such parties cannot
resolve the dispute, such Dispute shall be resolved in the jurisdiction of the
defendant party by binding arbitration in accordance with the then existing
commercial arbitration rules of The CPR institute for Dispute Resolution, 366
Madison Avenue, New York, NY 10017.

	
  9240 Trade Place, Suite
  100  •  San Diego, CA 92126

  
	
  Direct: (858)
  547-7800  •  Facsimile: (858)
  693-5989  •  www.cardinal.com/pts

  
	
  CONFIDENTIAL

  

 

 

X. Survival. These
Standard Terms and Conditions shall survive termination or expiration of this
Quotation.

Section
9. Project Approval and Authorization

By signing below, Urigen
agrees to the project details as set forth in this Quotation,

 

	
  Urigen, Inc.

  	
   

  	
  Cardinal Health PTS, LLC

  
	
   

  	
   

  	
   

  
	
   /s/ William
  J. Garner

  	
   

  	
  /s/ Richard Bunnell, Ph.D.

  
	
  Signature

  	
   

  	
  Signature

  
	
   

  	
   

  	
   

  
	
  William J. Garner

  	
   

  	
  Richard Bunnell, Ph.D.

  
	
  Printed Name

  	
   

  	
  Printed Name

  
	
   

  	
   

  	
   

  
	
  CEO

  	
   

  	
  Director, Dosage Form Design

  
	
  Title

  	
   

  	
  Title

  
	
   

  	
   

  	
   

  
	
  7-25-05

  	
   

  	
  7-22-05

  
	
  Date

  	
   

  	
  Date

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  PO Number

  	
   

  	
   

  

Please sign and
return a copy of the Quotation Approval Page via fax to Nick Sanna at 

858-693-5989 or email at nick.sanna@cardinal.com.

All invoicing is to be
sent directly to (please fill out, unless
provided previously):

	
  

  	
   

  	
  Company: Urigen, Inc.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
  William J. Garner

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Department:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Telephone Number:

  	
  917-653-0470

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Address:

  	
  1701 Jackson Street, 102

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  San Francisco, CA 94109

  	
   

  
								

 

	
  9240 Trade Place, Suite
  100  •  San Diego, CA 92126

  
	
  Direct: (858)
  547-7800  •  Facsimile: (858)
  693-5989  •  www.cardinal.com/pts

  
	
  CONFIDENTIALExhibit 10.1

ON THE GO HEALTHCARE, INC.

2007 STOCK OPTION PLAN
Dated: June 6, 2007

Article I.    Purposes of the Plan

The purposes of this Stock Option Plan are to attract and retain the best
available personnel, to provide additional incentive to Employees,
Directors and Consultants, and to promote the success of the Company's
business.

Article II.   Definitions

As used herein, the following definitions shall apply:

2.01   "Administrator" means the Board or any of the Committees appointed
        to administer the Plan.

2.02   "Applicable Laws" means the legal requirements relating to the
        administration of share incentive plans, if any, under applicable
        provisions of the U.S. federal securities laws, the U.S. state
        corporate and securities laws, the Code, the rules of any applicable
        stock exchange or national market system, and the laws and rules of
        any jurisdiction outside the U.S. applicable to Options including
        Canadian laws, SARs or Restricted Shares granted to residents
        therein.

2.03   "Board" means the Board of Directors of the Company.

2.04   "Code" means the U.S. Internal Revenue Code of 1986, as amended.

2.05   "Committee" means any committee appointed by the Board to administer
        the Plan, provided that the Committee shall consist of not fewer than
        two (2) members of the Board, and shall, following the Registration
        Date and, solely to the extent required to comply with Applicable Laws,
        be composed of "non-employee" directors within the meaning of
        Rule 16b-3 as promulgated under the Exchange Act and "outside
        directors" within the meaning of the Code.  To the extent the Plan
        is administered by the Board, the term "Committee" shall refer to
        the Board.

2.06   "Common Share" means a share of US$0.0001 par value of the Company.

2.07   "Company" means On the Go Healthcare, Inc., a company incorporated
        under the laws of Delaware.

2.08   "Consultant" means any person (other than an Employee or a Director)
        who is engaged by the Company or any Related Entity to render
        consulting or advisory services to the Company or such Related Entity
        or any other selective persons the Administrator determines provides,
        directly or indirectly, bona fide value to the Company or any Related
        Entity.

2.09   "Continuous Service" means that the provision of services to the Company
        or a Related Entity in any capacity of Employee, Director, or
        Consultant, is not interrupted or terminated.  Continuous Service
        shall not be considered interrupted in the case of:

<PAGE>

        (i)   any approved leave of absence;

        (ii)  transfers among the Company, any Related Entity, or any
              successor, in any capacity of Employee, Director, or
              Consultant; or

        (iii) any change in status as long as the individual remains in the
              service of the Company or a Related Entity in any capacity of
              Employee, Director, or Consultant (except as otherwise provided
              in the Option Agreement).

        An approved leave of absence shall include sick leave, maternity leave,
        or any other authorized personal leave.

2.10   "Corporate Transaction" means any of the following transactions to which
        the Company is a party:

        (i)   a merger or consolidation or reorganization in which the Company
              is not the surviving entity; or

        (ii)  the sale, transfer or other disposition of all or substantially
              all of the assets of the Company (including the share capital of
              the Company's Subsidiaries).

2.11   "Director" means a member of the Board or the board of directors of any
        Related Entity.

2.12   "Disability" means that an Optionee is permanently unable to carry out
        the responsibilities and functions of the position held by the Optionee
        by reason of any medically determinable physical or mental impairment
        as determined by the Administrator.  An Optionee will not be considered
        to have incurred a Disability unless he or she furnishes proof of such
        impairment sufficient to satisfy the Administrator in its discretion.

2.13   "Effective Date" means the date on which a Grant of Options and/or SARs
        and/or Restricted Shares shall take effect in accordance with Option
        Agreement.

2.14   "Employee" means any person, including an Officer or Director, who is an
        employee of the Company or any Related Entity.  The payment of an
        independent director's fee by the Company or a Related Entity shall
        not be sufficient to constitute "employment" of such person by the
        Company.

2.15   "Exchange Act" means the U.S. Securities Exchange Act of 1934, as
        amended.

2.16   "Fair Market Value" means, as of any date, the value of Common Shares
        as follows:

       (a) Where there exists a public market for the Common Shares, the Fair
           Market Value shall be:

                (i)   the closing price for a Share for the last market trading
                      day prior to the time of the determination (or, if no
                      closing price was reported on that date, on the last
                      trading date on which a closing price was reported) on
                      the stock exchange determined by the Administrator to be
                      the primary market for the Common Shares or the Nasdaq
                      National Market, whichever is applicable; or

<PAGE>

                (ii)  if the Common Shares are not traded on any such exchange,
                      or national market system, the average of the closing
                      bid and asked prices of a Share on the Nasdaq Small
                      Cap Market for the day prior to the time of the
                      determination (or, if no such prices were reported on
                      that date, on the last date on which such prices were
                      reported), in each case, as reported in The Wall Street
                      Journal or such other source as the Administrator deems
                      reliable.

       (b) In the absence of an established market for the Common Shares of
           the type described in (a), above, the Fair Market Value thereof
           shall be determined by the Administrator in good faith by reference
           to:

                (i)   the valuation price made by an independent appraiser
                      appointed by the Administrator;

                (ii)  the placing price of the latest private placement of the
                      Shares; and

                (iii) the development of the Company's business operations
                      since such latest private placement.

2.17  "Grant" means the number of Options and/or Stock Appreciation Rights
       and/or Restricted Shares and/or Restricted Share Units granted to an
       Optionee at any time in accordance with Section 6 hereof.

2.18  "Immediate Family" means any child, stepchild, grandchild, parent,
       stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
       mother-in-law, father-in-law, son-in-law, daughter-in-law,
       brother-in-law, or sister-in-law, including adoptive relationships,
       any person sharing the Optionee's household (other than a tenant or
       employee), a trust in which these persons (or the Optionee) have more
       than fifty percent (50%) of the beneficial interest, a foundation in
       which these persons (or the Optionee) control the management of
       assets, and any other entity in which these persons (or the Optionee)
       own more than fifty percent (50%) of the voting interests.

2.19  "Liquidation Event" means a complete dissolution or liquidation of the
       Company.

2.20  "Non-Statutory Stock Option" means an Option not intended to qualify as
       an Incentive Stock Option within the meaning of Section 422 of the Code.

2.21  "Officer" means a person who is an officer of the Company or a Related
       Entity within the meaning of Section 16 of the Exchange Act and the
       rules and regulations promulgated thereunder or, to the extent
       applicable, other Applicable Laws.

2.22  "Option" means an option to purchase Shares pursuant to an Option
       Agreement granted under the Plan.

2.23   "Optionee" means an Employee, Director, or Consultant who receives a
        Grant under the Plan.

2.24   "Option Agreement" means the written agreement evidencing the grant of
        an option and/or SARs and/or Restricted Shares executed by the Company
        and the Optionee, including any amendments thereto.

2.25   "Option Period" means the period commencing on the Effective Date of a
        Grant and ending no later than on the day prior to the tenth
        anniversary of such Effective Date.

<PAGE>

2.26   "Parent" means a "parent corporation", whether now or hereafter
        existing, as defined in Section 424(e) of the Code or, to the extent
        applicable, other Applicable Laws.

2.27   "Plan" means this 2007 Stock Option Plan of On the Go Healthcare, Inc.,
        as set forth herein and as may be amended from time to time.

2.28   "Registration Date" means the first to occur of:

        (a) the closing of the first sale to the general public of:

                (i)  the Common Shares; or

                (ii) the same class of securities of a successor corporation
                     (or its Parent) issued pursuant to a Corporate Transaction
                     in exchange for or in substitution of the Common Shares,
                     pursuant to a registration statement filed with and
                     declared effective by the Securities and Exchange
                     Commission under the Securities Act or an equivalent
                     thereof in a jurisdiction outside the U.S.;

        and

        (b) in the event of a Corporate Transaction, the date of the
            consummation of the Corporate Transaction if the same class of
            securities of the successor corporation (or its Parent) issuable in
            such Corporate Transaction shall have been sold to the general
            public pursuant to a registration statement filed with and declared
            effective by the Securities and Exchange Commission under the
            Securities Act or an equivalent thereof in a jurisdiction outside
            the U.S., on or prior to the date of consummation of such Corporate
            Transaction.

2.29   "Related Entity" means any Parent, Subsidiary and any other corporation,
        partnership, limited liability company or other business entity in
        which the Company, its Parent or a Subsidiary holds a substantial
        ownership interest, directly or indirectly.

2.30   "Securities Act" means the U.S. Securities Act of 1933, as amended.

2.31   "SAR" means a Stock Appreciation Right granted to an Optionee under
        this Plan.

2.32   "Shares" mean Common Shares of the Company.

2.33   "Subsidiary" means a "subsidiary corporation", whether now or hereafter
        existing, as defined in Section 424(f) of the Code or, to the extent
        applicable, other Applicable Laws.

Article III.  Shares Subject to the Plan

3.01   Subject to the provisions of Section 10.01 below, the maximum aggregate
       number of Shares with respect to which Grants may be made under the
       Plan shall not exceed 100,000,000 shares.

<PAGE>

3.02   Any Shares covered by a Grant (or portion of a Grant) which is forfeited
       or cancelled, expires or is settled in cash or otherwise, shall be
       deemed not to have been issued for purposes of determining the maximum
       aggregate number of Shares which may be issued under the Plan.  If any
       unissued Shares are retained by the Company upon exercise of a Grant in
       order to satisfy the exercise price for such Grant or any withholding
       taxes due with respect to such Grant, such retained Shares subject to
       such Grant shall become available for future issuance under the Plan
       (unless the Plan has terminated).  Shares that actually have been
       issued under the Plan pursuant to a Grant shall not be returned to
       the Plan and shall not become available for future issuance under
       the Plan.

Article IV.   Administration of the Plan

4.01   Plan Administrator.  The Committee shall administer the Plan in
       accordance with its terms.

4.02   Powers of the Administrator.  Subject to Applicable Laws and the
       provisions of the Plan (including any other powers given to the
       Administrator hereunder), and except as otherwise provided by the Board,
       the Administrator shall have the authority, in its discretion:

        (a) to determine the eligibility of Grants, the classes of bands and
            the range of number of Shares covered in each Band, to authorize
            the Chief Executive Officer and Executive Management Team to
            determine number of shares of each Grant;

        (b) to approve forms of Option Agreements for use under the Plan;

        (c) to determine to grant Options with or without SARs;

        (d) to determine the Exercise Price applicable to the Share covered
            by each Option;

        (e) to determine the Option Period applicable thereto;

        (f) to establish additional terms, conditions, rules or procedures to
            accommodate the rules or laws of applicable foreign jurisdictions
            and to afford Optionees favorable treatment under such rules or
            laws; provided, however, that no Grant shall be granted under any
            such additional terms, conditions, rules or procedures with terms
            or conditions which are inconsistent with the provisions of the
            Plan;

        (g) to amend the terms of any outstanding Grant granted under the Plan,
            and to reduce the exercise price of any Option or SAR to the then
            current Fair Market Value if the Fair Market Value of the Shares
            covered by such Grant shall have declined since the date the Grant
            was granted and to make any other amendments or adjustments to any
            Grant that the Administrator determines, in its discretion and
            under the authority granted to it under this Plan, to be necessary
            or advisable, provided that the exercise price shall never fall
            below the nominal or par value of the Shares, and that any such
            amendment or adjustment that would adversely affect the Optionee's
            rights under an outstanding Grant shall not be made without the
            Optionee's written consent;

        (h) to construe and interpret the terms of the Plan and Grants,
            including without limitation, any notice of Grant or Option
            Agreement, granted pursuant to the Plan; and

        (j) to take such other action, not inconsistent with the terms of the
            Plan, as the Administrator deems appropriate.

<PAGE>

Article V.    Eligibility

Options may be granted to Employees, Directors, and Consultants.  An Employee,
Director, or Consultant who has been granted a Grant may, if otherwise
eligible, be granted additional Grants.  Grants may be granted to such
Employees, Directors, or Consultants who are residing in foreign jurisdictions
as the Administrator may determine from time to time.

Article VI.   Type of Grants; Terms and Conditions of Grants

Grants under the Plan may consist of one or more of the following: Options,
SARs, or Restricted Shares (which may be granted as Restricted Share units).
Restricted Stock may be registered on a Form S-8 prior or subsequent to any
grants. Awards of Restricted Shares may provide the Optionee with dividends
or dividend equivalents and voting rights prior to vesting.  Additionally,
shares of common stock may be granted as free-trading shares if the shares of
common stock are registered on a Form S-8.  Each Grant shall be designated in
the Option Agreement.

6.01   Options

        (a) Option Designation.  Options shall be designated as Non-Statutory
            Stock Option.

        (b) Option Exercise Price.  The exercise price of an Option shall be
            as follows:

                (i)  granted to a person who, at the time of the grant of such
                     Non-Statutory Stock Option owns shares representing more
                     than ten percent (10%) of the voting power of all classes
                     of shares of the Company or any Parent or Subsidiary, the
                     per Share exercise price shall be not less than one
                     hundred percent (100%) of the Fair Market Value per
                     Share on the date of grant; or

                (ii) granted to a person other than a person described in the
                     preceding paragraph, the per Share exercise price shall
                     be not less than eighty five percent (85%) of the Fair
                     Market Value per Share on the date of grant.

        (c) Consideration.  In addition to any other types of consideration the
            Administrator may determine, the Administrator is authorized to
            accept as consideration for Shares issued under the Plan the
            following:

                (i)   cash or check

                (ii)  cancellation of indebtedness owed by the Company to the
                      Optionee;

                (iii) promissory note;

                (iv)  Shares previously acquired by the Optionee valued at the
                      Fair Market Value at the time of the exercise;

                (v)   withholding from delivery to the Optionee that number of
                      whole Shares having a Fair Market Value at the time of
                      the exercise equal to the exercise price payable to the
                      Company upon exercise of the Option; or

                (vi)  any combination of the foregoing methods of payment.

        (d) Easy-Sale Exercise.

<PAGE>

                (i)   Exercise/Sale.  An Option Agreement may, but need not,
                      provide that, if Shares are publicly traded, all or part
                      of the exercise price of an Option and any withholding
                      taxes may be paid by the delivery (on a form prescribed
                      by the Company) of an irrevocable direction to a
                      securities broker approved by the Company to sell
                      Shares and to deliver all or part of the sales proceeds
                      to the Company.

                (ii)  Exercise/Pledge.  An Option Agreement may, but need not,
                      provide that, if Shares are publicly traded, all or part
                      of the exercise price of an Option and any withholding
                      taxes may be paid by the delivery (on a form prescribed
                      by the Company) of an irrevocable direction to pledge
                      Shares to a securities broker or lender approved by the
                      Company, as security for a loan, and to deliver all or
                      part of the loan proceeds to the Company.

6.02   SARs.

        (a) Grant.  SARs may be granted in tandem with an Option, in addition
            to an Option, or may be freestanding and unrelated to an Option.
            SARs granted in tandem or in addition to an Option may be granted
            either at the same time as the Option or at a later time.  SARs
            shall vest and become exercisable at a rate determined by the
            Administrator, and shall remain exercisable for such period as
            specified by the Administrator.  A SAR shall entitle the Optionee
            to receive from the Company an amount equal to the excess of the
            Fair Market Value of a Share on the exercise of the SAR over the
            Fair Market Value of a Share on the date of grant or, in the case
            of an SAR granted in tandem with an Option, the per Share exercise
            price applicable to such Option.

        (b) Settlement.  The Administrator shall determine in its sole
            discretion whether the SAR shall be settled in cash, Shares, or a
            combination of cash and Shares.  In no event may any Optionee
            receive grants of SARs with respect to more than 350,000 Shares in
            any calendar year.

6.03   Restricted Shares.

        (a) Grant.  Restricted Shares may be granted in the form of Shares or
            share units having a value equal to an identical number of Shares.
            The employment conditions and the length of the period for vesting
            of Restricted Shares shall be established by the Administrator at
            time of grant.  In the event that a share certificate is issued in
            respect of Restricted Shares, such certificate shall be registered
            in the name of the Optionee but shall be held by the Company until
            the end of the restricted period.  During the restricted period,
            Restricted Shares may not be sold, assigned, transferred or
            otherwise disposed of, or pledged or hypothecated as collateral
            for a loan or as security for the performance of any obligation
            or for any other purpose as the Administrator shall determine.

        (b) Settlement.  The Administrator shall determine in its sole
            discretion whether Restricted Shares granted in the form of share
            units shall be paid in cash, Shares, or a combination of cash and
            Shares.

<PAGE>

6.04   Conditions of Grant; Vesting, and Repurchase Right.  Subject to the
       terms of the Plan, the Administrator shall determine the provisions,
       terms, and conditions of each Grant including, but not limited to, the
       Grant vesting schedule, repurchase provisions, rights of first refusal,
       forfeiture provisions, form of payment (cash, Shares, or other
       consideration) upon settlement of the Grant, payment contingencies,
       and satisfaction of any performance criteria, provided, however,
       unless specifically provided otherwise in the relevant Option Agreement,
       one fourth (1/4th) of the Grant shall vest at each of 1st, 2nd, 3rd,
       and 4th anniversaries following the issuance of such Grant so long as
       the Optionee provides Continuous Service to the Company.

6.05   Acquisitions and Other Transactions.  The Administrator may issue Grants
       under the Plan in settlement, assumption or substitution for,
       outstanding Grants or obligations to grant future Grants in connection
       with the Company or a Related Entity acquiring another entity, an
       interest in another entity or an additional interest in a Related
       Entity whether by merger, share purchase, asset purchase, or other form
       of transaction.

6.06   Deferral of Grant Payment.  The Administrator may establish one or more
       programs under the Plan to permit selected Optionees the opportunity to
       elect to defer receipt of consideration upon exercise of a Grant,
       satisfaction of performance criteria, or other event that absent the
       election would entitle the Optionee to payment or receipt of Shares or
       other consideration under a Grant.  The Administrator may establish the
       election procedures, the timing of such elections, the mechanisms for
       payments of, and accrual of interest or other earnings, if any, on
       amounts, Shares or other consideration so deferred, and such other
       terms, conditions, rules and procedures that the Administrator deems
       advisable for the administration of any such deferral program.

6.07   Award Exchange Programs.  The Administrator may establish one or more
       programs under the Plan to permit selected Optionees to exchange a
       Grant under the Plan for one or more other types of Grants under the
       Plan on such terms and conditions as determined by the Administrator
       from time to time.

6.08   Separate Programs.  The Administrator may establish one or more separate
       programs under the Plan for the purpose of issuing particular forms of
       Grants to one or more classes of Optionees on such terms and conditions
       as determined by the Administrator from time to time.

6.09   Early Exercise.  The Option Agreement may, but need not, include a
       provision whereby the Optionee may elect, at any time while being an
       Employee, Director, or Consultant, to exercise any part or all of the
       Grant prior to full vesting of the Grant.  Any unvested Shares received
       pursuant to such exercise may be subject to a repurchase right in favor
       of the Company or a Related Entity or to any other restriction the
       Administrator determines to be appropriate.

6.10   Option Period.  The Option Period shall be the term stated in the Option
       Agreement up to ten (10) years from the Effective Date of Grant thereof.

6.11   Transferability of Grants.  No Grant may be sold, pledged, assigned,
       hypothecated, transferred, or disposed of in any manner other than by
       will or by the laws of descent or distribution and may be exercised,
       during the lifetime of the Optionee, only by the Optionee; provided,
       however, during the lifetime of the Optionee, SARs may be transferred
       by gift to members of the Optionee's Immediate Family to the extent and
       manner determined by the Administrator.

6.12   Time of Grants.  The date of grant of a Grant shall for all purposes
       be the date on which the Administrator makes the determination to grant
       such Grant, or such other date as is determined by the Administrator.
       Notice of the grant determination shall be given to each Employee,
       Director, or Consultant to whom a Grant is so granted within a
       reasonable time after the date of such grant.

<PAGE>

6.13   Buyout Provisions.  The Administrator may at any time offer to buy out
       for a payment in cash or Shares or other consideration, any Grant
       previously granted based on such terms and conditions as the
       Administrator shall establish and communicate to the Optionee at
       the time such offer is made.

Article VII.  Withholding

The Company shall have the right to deduct from any payment to be made pursuant
to the Plan the amount of any taxes required by law to be withheld therefrom,
or to require an Optionee to pay to the Company such amount required to be
withheld prior to the issuance or delivery of any Shares or the payment of cash
under the Plan.  The Administrator may, in its discretion, permit an Optionee
to elect to satisfy such withholding obligation by having the Company retain
the number of Shares whose Fair Market Value equals the amount required to be
withheld.  Any fraction of a Share required to satisfy such obligation shall
be disregarded and the amount due shall instead be paid in cash by the
Optionee.

Article VIII. Exercise of Grant

8.01   Procedure for Exercise; Rights as a Shareholder.

        (a) Any Grant granted hereunder shall be exercisable at such times
            and under such conditions as determined by the Administrator under
            the terms of the Plan and specified in the Option Agreement.

        (b) A Grant shall be deemed to be exercised when written notice of such
            exercise has been given to the Company, as in a form required
            under the applicable Option Agreement, in accordance with the
            terms of the Grant by the person entitled to exercise the Grant
            and full payment for the Shares is made with respect to which the
            Grant is exercised.  Until the issuance (as evidenced by the
            appropriate entry on the books of the Company or of a duly
            authorized transfer agent of the Company) of the share certificate
            evidencing such Shares, no right to vote or receive dividends or
            any other rights as a shareholder shall exist with respect to
            Shares subject to a Grant, notwithstanding the exercise of an
            Option or other Grant.  The Company shall issue (or cause to be
            issued) such share certificate as soon as practicable following
            the exercise of the Grant.  No adjustment will be made for a
            dividend or other right for which the record date is prior to the
            date the share certificate is issued, except as provided in the
            Option Agreement or Section 10, below.

8.02   Exercise of Option or SAR Following Termination of Continuous Service.
       If the Optionee's Continuous Service is terminated for any reason other
       than death or Disability, such Optionee shall have the right to
       exercise the Option or SAR at any time within thirty (30) days (or such
       other period of time not exceeding three (3) months as is determined
       by the Administrator at the time of granting the Option), following the
       date such Optionee ceases his or her Continuous Service to the extent
       that such Optionee was entitled to exercise the Option or SAR at the
       date of such termination; provided, however, that no Option or SAR
       shall be exercisable after the expiration of the term set forth in the
       applicable Option Agreement.  To the extent that such Optionee was not
       entitled to exercise the Option or SAR at the date of such termination,
       or if such Optionee does not exercise such Option or SAR (which such
       Optionee was entitled to exercise) within the time specified herein,
       the Option or SAR shall terminate.

<PAGE>

8.03   Death or Disability of Optionee.  If an Optionee's Continuous Service
       is terminated due to death or Disability, the Option or SAR may be
       exercised at any time within six (6) months following the date of death
       or termination of employment due to Disability, in the case of death, by
       the Optionee's estate or by a person who acquired the right to exercise
       the Option or SAR by bequest or inheritance, or, in the case of
       Disability, by the Optionee, but in any case only to the extent the
       Optionee was entitled to exercise the Option or SAR at the date of his
       or her termination of Continuous Service by death or Disability;
       provided, however, that no Option or SAR shall be exercisable after the
       expiration of the term set forth in the Option Agreement.  To the extent
       that such Optionee was not entitled to exercise such Option or SAR at
       the date of his or her termination of employment by death or Disability
       or if such Option or SAR is not exercised (to the extent it could be
       exercised) within the time specified herein, the Option or SAR shall
       terminate.

8.04   Extension of Time to Exercise.  Notwithstanding anything to the contrary
       in this Section 8, the Administrator may at any time and from time to
       time prior to the termination of a Non-statutory Stock Option, with
       the consent of the Optionee, extend the period of time during which
       the Optionee may exercise his or her Non-statutory Stock Option
       following the date the Optionee's ceases Continuous Services; provided,
       however, that:

        (a) the maximum period of time during which a Non-statutory Stock
            Option shall be exercisable following such termination date shall
            not exceed an aggregate of six (6) months;

        (b) the Non-statutory Stock Option shall not become exercisable after
            the expiration of the term of such Option as set forth in the
            Option Agreement as a result of such extension; and

        (c) notwithstanding any extension of time during which the
            Non-statutory Stock Option may be exercised, such Option, unless
            otherwise amended by the Administrator, shall only be exercisable
            to the extent to which the Optionee was entitled to exercise it
            on the date the Optionee ceased Continuous Services.

        To the extent that such Optionee was not entitled to exercise the
        Option at the date of such termination, or if such Optionee does not
        exercise an Option which the Optionee was entitled to exercise within
        the time specified herein, the Option shall terminate.

Article IX.   Conditions Upon Issuance of Shares

9.01   No Violation of Law.  Shares shall not be issued pursuant to a Grant or
       the exercise of a Grant unless the exercise of such Grant and the
       issuance and delivery of such Shares pursuant thereto shall comply with
       all Applicable Laws, and the Administrator may further subject any
       issuance of Shares to the approval of counsel for the Company with
       respect to such compliance.

9.02   Execution of Documents.  As a condition to the exercise of a Grant,
       the Administrator may require the person exercising such Grant to
       execute an investment representation statement acceptable to the
       Company or a share purchase agreement acceptable to the Company, each
       in forms approved by the Administrator from time to time, in addition
       to the any other instrument the Administrator deems necessary or
       advisable.

<PAGE>

Article X.    Adjustments Upon Changes in Capitalization or Corporate
              Transaction

10.01  Adjustments upon Changes in Capitalization.  Subject to any required
       action by the shareholders of the Company, the number of Shares covered
       by each outstanding Grant, and the number of Shares which have been
       authorized for issuance under the Plan but as to which no Grants have
       yet been granted or which have been returned to the Plan, the exercise
       or purchase price of each such outstanding Grant, as well as any other
       terms that the Administrator determines require adjustment shall be
       proportionately adjusted for:

        (a) any increase or decrease in the number of issued Shares resulting
            from a share split, reverse share split, share dividend,
            combination or reclassification of the Shares, or similar
            transaction affecting the Shares;

        (b) any other increase or decrease in the number of issued Shares
            effected without receipt of consideration by the Company; or

        (c) as the Administrator may determine in its discretion, any other
            transaction with respect to Shares to which Section 424(a) of the
            Code applies or a similar transaction; provided, however, that
            conversion of any convertible securities of the Company shall not
            be deemed to have been "effected without receipt of consideration."

       Such adjustment shall be made by the Administrator and its
       determination shall be final, binding and conclusive.  Except as the
       Administrator determines, no issuance by the Company of shares of any
       class, or securities convertible into shares of any class, shall
       affect, and no adjustment by reason hereof shall be made with respect
       to, the number or price of Shares subject to a Grant.

10.02  Corporate Transaction.  In the event of a proposed Corporate
       Transaction, subject to the actual consummation of the proposed
       transaction, each outstanding Grant shall automatically become fully
       vested and exercisable, unless the Grant is assumed or substituted with
       an equivalent option or right by the successor corporation or the Parent
       or Subsidiary thereof.  If the successor corporation refuses to assume
       or substitute for the Grant, the Administrator shall notify the Optionee
       that the Grant shall be fully vested and exercisable with respect to all
       of the Shares underlying the Grant (including Shares as to which it
       would not otherwise be vested or exercisable) for a period of fifteen
       (15) days from the date of such notice.  If the Grant thus becomes fully
       vested and exercisable but is not exercised during this fifteen (15) day
       period, it shall terminate immediately prior to the effective time of
       such Corporate Transaction.  For the purposes of this Section 10.02,
       the Grant shall be considered assumed or substituted with an equivalent
       option or right if, in connection with the Corporate Transaction, the
       Grant is replaced with a comparable option or right with respect to
       shares of the successor corporation or Parent or Subsidiary thereof or
       is replaced with a cash incentive program of the successor corporation
       or Parent or Subsidiary thereof which preserves the compensation element
       of such Grant existing at the time of the Corporate Transaction and
       provides for subsequent payout in accordance with the same vesting
       schedule applicable to such Grant.  The determination of Grant
       comparability above shall be made by the Administrator and its
       determination shall be final, binding and conclusive.

<PAGE>

10.03  Liquidation Event.  In the event of a proposed Liquidation Event, the
       Administrator shall notify each Optionee of the proposed event at least
       twenty (20) days prior to the proposed effective date of the Liquidation
       Event.  The Administrator in its discretion may provide for an Optionee
       to have the right to exercise his or her Grant until ten (10) days prior
       to the proposed effective date for the Liquidation Event with respect
       to all Shares underlying the Grant (including Shares as to which it
       would not otherwise be vested or exercisable), subject to the actual
       completion of the Liquidation Event at the time and in the manner
       contemplated.  In addition, the Administrator may provide that any
       Company repurchase option applicable to any Shares issued upon grant
       or an exercise of a Grant shall lapse as to all Shares, subject to the
       actual completion of the Liquidation Event at the time and in the manner
       contemplated.  Any unexercised Grant  shall terminate immediately prior
       to effective time of the Liquidation Event.

Article XI.   Effective Date and Term of Plan

The Plan, and any amendments to the Plan, shall become effective upon its
adoption by the Board.  It shall continue in effect until the end of 2017
unless sooner terminated.  Subject to Section 17, below, and Applicable Laws,
Grants may be granted under the Plan upon its becoming effective.

Article XII.  Amendment, Suspension or Termination of the Plan

The Board may at any time amend, suspend or terminate the Plan.  No Grant may
be granted during any suspension of the Plan or after termination of the Plan.
Any amendment, suspension or termination of the Plan (including termination of
the Plan pursuant to this Section 12) shall not affect Grants already granted,
and such Grants shall remain in full force and effect as if the Plan had not
been amended, suspended or terminated, unless mutually agreed otherwise between
the Optionee and the Administrator, which agreement must be in writing and
signed by the Optionee and the Company.

Article XIII. Availability of Shares; No Issuance in Violation of Law

13.01  Availability of Shares.  The Company, during the term of the Plan, will
       at all times keep available such number of unissued Shares as shall be
       sufficient to satisfy the requirements of the Plan.

13.02  No Issuance in Violation of Law.  The inability of the Company to obtain
       authority from any regulatory body having jurisdiction under Applicable
       Law, which authority is deemed by the Company's counsel to be necessary
       to the lawful issuance and sale of any Shares hereunder, relieve the
       Company of any liability in respect of the failure to issue or sell
       such Shares as to which such requisite authority shall not have been
       obtained.

Article XIV.  No Effect on Terms of Employment/Consulting Relationship

The Plan shall not confer upon any Optionee any right with respect to the
Optionee's Continuous Service, nor shall it interfere in any way with his
or her right or the Company's or a Related Entity's right to terminate the
Optionee's Continuous Service at any time, with or without cause.

<PAGE>

Article XV.   No Effect on Retirement and Other Benefit Plans

Except as specifically required by law or provided in a retirement or other
benefit plan of the Company or a Related Entity, Grants shall not be deemed
compensation for purposes of computing benefits or contributions under any
retirement plan of the Company or a Related Entity, and shall not affect any
benefits under any other benefit plan of any kind or any benefit plan
subsequently instituted under which the availability or amount of benefits is
related to level of compensation.

Article XVI.  Liability of the Company; Consents

16.01  Consents.  Optionee shall be responsible for obtaining any governmental
       or other official consent that may be required by any country or
       jurisdiction in order to permit the grant or exercise of any Grant.
       Neither the Company nor any Related Entity shall be responsible for any
       failure by an Optionee to obtain such consent or for any tax or other
       liability to which an Optionee may become subject to as a result of his
       or her participation in the Plan.

<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00124-of-00352.parquet"}]]